Population Level Screening to Detect Early Stage Type 1 Diabetes

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/41/85/f8/4185f88d-383b-eb58-69c6-90eb39860bc4/mza_18445452371816496660.jpg/600x600bb.jpg

Diabetes Insights - Breakthroughs and Innovators

EASD - European Association for the Study of Diabetes

45 episodes

2 weeks ago

EASD presents: Diabetes Insights - Breakthroughs and Innovators Join us for expert interviews and discussions on the latest advances in diabetes research. Discover how groundbreaking medicines and cutting-edge technologies are shaping the future of diabetes treatment and management. Get inspired by the stories of distinguished researchers whose discoveries and contributions have transformed our understanding of diabetes. These podcasts were recorded at the EASD Annual Meeting 2024 in Madrid, Spain. You can learn more about the research discussed by watching the scientific presentations in the EASD Media Centre (https://www.easd.org/media-centre/home.html). New episode released every Friday.

Science

Education

RSS

All content for Diabetes Insights - Breakthroughs and Innovators is the property of EASD - European Association for the Study of Diabetes and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Science

Education

https://images.podigee-cdn.net/0x,s4BFfjpwXUZf2P3Lz-39lGA-rQZPg0Lz2EVgOih9QiwI=/https://main.podigee-cdn.net/uploads/u70008/2b787fd6-a45b-4dfa-8d3f-f9af7100a9f2.jpg

Population Level Screening to Detect Early Stage Type 1 Diabetes

Diabetes Insights - Breakthroughs and Innovators

14 minutes

1 month ago

Population Level Screening to Detect Early Stage Type 1 Diabetes

In this episode, leading experts Anette Ziegler (Helmholtz Munich), Chantal Mathieu (KU Leuven & EASD President), and Anastasia Albanese-O’Neill (Breakthrough T1D) join EASD TV to discuss the emerging global consensus on screening for early-stage type 1 diabetes. They explore why population-wide screening is now considered both feasible and essential, how early detection can prevent DKA and enable access to disease-modifying therapies, and what the new guidance means for clinicians, health systems, and policymakers. From optimal screening ages and two-step testing strategies to implementation challenges, cost-effectiveness, and the promise of prevention, this conversation outlines one of the most significant shifts in type 1 diabetes care in decades.